Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer

Auranofin (AF) is an FDA-approved antirheumatic drug with anticancer properties that acts as a thioredoxin reductase 1 (TrxR) inhibitor. The exact mechanisms through which AF targets cancer cells remain elusive. To shed light on the mode of action, this study provides an in-depth analysis on the mol...

Full description

Bibliographic Details
Main Authors: Laurie Freire Boullosa, Jinthe Van Loenhout, Tal Flieswasser, Jorrit De Waele, Christophe Hermans, Hilde Lambrechts, Bart Cuypers, Kris Laukens, Esther Bartholomeus, Vasiliki Siozopoulou, Winnok H. De Vos, Marc Peeters, Evelien L.J. Smits, Christophe Deben
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Redox Biology
Subjects:
Auranofin
Thioredoxin reductase
Non-small cell lung cancer
Mutant p53
Oxidative stress
Cancer cell death
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231721000975

Internet

http://www.sciencedirect.com/science/article/pii/S2213231721000975

Similar Items